A chimeric switch receptor for macrophages and its application
By constructing a chimeric switch receptor and combining it with lipid nanoparticles and a hydrogel-liposome system, the transformation of M2 macrophages to M1 was achieved, solving the problems of high cost and side effects in the treatment of renal cancer and achieving precise drug delivery and anti-tumor effects in local targeted tumor therapy.
Patent Information
- Application Number
- CN202411543869.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-31
- Publication Date
- 2025-09-19
- Estimated Expiration
- 2044-10-31
AI Technical Summary
Existing treatments for kidney cancer have problems such as high cost, severe side effects, and easy development of drug resistance. In addition, immunotherapy is not effective, especially for patients with advanced kidney cancer. There is a lack of effective new treatment strategies and drugs.
A chimeric switch receptor is constructed, including the extracellular domain of IL-2α, IL-2β or IL-2γ receptor, the transmembrane domain of CD8 or CD28 and the intracellular domain of CD3ζ, TLR4, CD40 or Dectin1. Through lipid nanoparticle delivery system and hydrogel-liposome combined drug delivery system, the conversion of M2 macrophages to M1 type is achieved for local targeted tumor treatment.
It achieves the phagocytic killing effect of tumor cells, reduces toxic side effects, realizes precise drug delivery and anti-tumor effects for renal cancer, and avoids adverse reactions caused by systemic medication.